Anika Therapeutics (ANIK) 52.79 $ANIK
Global Anti-Adhesion Products Industry
PR Newswire - Mon Jun 27, 2:41PM CDT
This report analyzes the worldwide markets for Anti-Adhesion Products in US$ Thousand by the following three major Application Areas: General/Abdominal Surgery, Pelvic/Gynecological Surgery, and Other Surgical Procedures. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 21 companies including many key and niche players such as -
ANIK: 52.79 (-0.51)
Anika to Present at the Singular Research 11th Annual Spring Select Conference on June 9, 2016
BusinessWire - Thu Jun 02, 3:05PM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"
technology, today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will make a presentation at the Singular Research 11th Annual Spring Select Conference on Thursday, June 9, 2016 at 2:30 pm PT. The conference is being held at the Hilton hotel in San Francisco, CA.
ANIK: 52.79 (-0.51)
Anika Announces European Commercial Launch of CINGAL for the Treatment of Pain Associated with Osteoarthritis
BusinessWire - Wed Jun 01, 8:05AM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA" technology, today announced the commercial launch of CINGAL(R), its third-generation viscosupplement, in the European Union. CINGAL, which will be initially available in Hungary, Czech Republic, Poland, Germany, and Italy, received CE Mark approval in March 2016 to treat pain associated with osteoarthritis. CINGAL will be marketed and sold in Europe by a network of experienced commercial partners under the terms of their respective commercialization agreements.
ANIK: 52.79 (-0.51)
Anika Therapeutics Announces Canadian Launch of CINGAL for the Treatment of Pain Associated with Osteoarthritis of the Knee
BusinessWire - Thu May 19, 8:05AM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA" technology, today announced the commercial launch of CINGAL(R), its third-generation viscosupplement, in Canada. CINGAL received Health Canada approval in October 2015 to treat pain associated with osteoarthritis of the knee.
ANIK: 52.79 (-0.51)
Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 55.01 (+0.85), OMED: 12.90 (-0.11), LGND: 126.76 (+0.90), ANIK: 52.79 (-0.51)
Alexion (ALXN) Lags Q1 Earnings & Revenues, Revises View
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:40PM CDT
Alexion (ALXN) reported earnings of 87 cents per share, below the Zacks Consensus Estimate of 91 cents.
EBS: 30.47 (+0.43), ALXN: 125.30 (+0.88), AEGR: 1.62 (-0.05), ANIK: 52.79 (-0.51)
Integra (IART) Beats on Q1 Earnings, Grows Organically
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:36PM CDT
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share (EPS) of 74 cents in the first quarter of 2016.
IART: 80.50 (-0.95), ANIP: 55.38 (-1.13), ANIK: 52.79 (-0.51), ALQA: 1.19 (unch)
GlaxoSmithKline (GSK) Q1 Earnings Lag, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:06PM CDT
Glaxo (GSK) reported first-quarter 2016 core earnings of 57 cents per American depositary share, missing the Zacks Consensus Estimate of 60 cents.
EBS: 30.47 (+0.43), GSK: 43.52 (+0.14), ANIK: 52.79 (-0.51), NVS: 82.31 (+0.18)
Baxalta (BXLT) Beats on Q1 Earnings, Set to Merge with Shire
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:41AM CDT
Baxalta's (BXLT) first-quarter 2016 earnings of 47 cents per share beat the Zacks Consensus Estimate by a penny.
BAX: 46.49 (-0.16), SHPG: 186.31 (-1.90), BXLT: 46.02 (-0.18), ANIK: 52.79 (-0.51)
Bristol-Myers (BMY) Tops Q1 Earnings, Updates 2016 View
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:27AM CDT
Bristol-Myers' (BMY) first-quarter 2016 earnings (excluding special items) of 74 cents per share easily beat the Zacks Consensus Estimate of 66 cents.
EBS: 30.47 (+0.43), PFE: 36.15 (+0.03), BMY: 75.39 (+0.11), ANIK: 52.79 (-0.51)
Celgene (CELG) Beats on Q1 Earnings, Updates '16 Outlook
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:05AM CDT
Celgene Corp. (CELG) reported first-quarter 2016 earnings of $1.18 per share (including share-based compensation expense), beating the Zacks Consensus Estimate of $1.05.
EBS: 30.47 (+0.43), AEGR: 1.62 (-0.05), ANIK: 52.79 (-0.51), CELG: 103.41 (-1.62)
Immunomedics (IMMU) Catches Eye: Stock Moves 10.8% Higher
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 7:15AM CDT
Immunomedics Inc. (IMMU) shares rose almost 11% in the last trading session.
IMMU: 2.30 (-0.18), ANIK: 52.79 (-0.51)
Downgrade Alert for Anika Therapeutics (ANIK)
Comtex SmarTrend(R) - Thu Apr 28, 3:36AM CDT
Anika Therapeutics (NASDAQ:ANIK) was downgraded from Outperform to Market Perform at Northland today. The stock closed yesterday at $44.64 on volume of 513,000 shares, above average daily volume of 148,000. There is potential upside of 14.2% for shares of Anika Therapeutics based on a current price of $44.64 and an average consensus analyst price target of $51.00. Anika Therapeutics shares have support at the 50-day moving average (MA) of $44.62 and additional support at the 200-day MA of $38.85.
ANIK: 52.79 (-0.51)
Anika beats 1Q profit forecasts
Automated Insights - Wed Apr 27, 4:05PM CDT
BEDFORD, Mass. (AP) _ Anika Therapeutics Inc. (ANIK) on Wednesday reported first-quarter earnings of $6.9 million.
ANIK: 52.79 (-0.51)
Anika Reports First Quarter 2016 Financial Results
BusinessWire - Wed Apr 27, 3:05PM CDT
--Commenced $25 million Accelerated Share Repurchase Program
ANIK: 52.79 (-0.51)
Bayer (BAYRY) Q1 Earnings Beat Estimates, Retains View
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 10:57AM CDT
Bayer (BAYRY) reported core earnings of $2.61 per share, above the Zacks Consensus Estimate of $2.48.
CYTX: 2.01 (unch), AEGR: 1.62 (-0.05), ANIK: 52.79 (-0.51)
New Strong Buy Stocks for April 27th
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:41AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
ALGN: 83.37 (+0.44), AMCX: 58.84 (-0.51), AEGR: 1.62 (-0.05), ANIK: 52.79 (-0.51), ADTN: 19.72 (+0.37)
Oncothyreon (ONTY) Catches Eye: Stock Moves 11.6% Higher
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 3:31AM CDT
Oncothyreon Inc (ONTY) shares rose almost 12% in the last trading session.
ANIK: 52.79 (-0.51), ONTY: 1.21 (+0.02)
Top 5 Stocks with Increasing Cash Flows
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 2:24PM CDT
One must look at a company's ability to produce cash - the lifeblood of business.
JBT: 63.77 (+1.14), FOR: 12.02 (-0.03), NSAT: 6.36 (-0.18), EBS: 30.47 (+0.43), ANIK: 52.79 (-0.51)
Biogen (BIIB) Tops on Q1 Earnings, Slight Revenue Miss
Arpita Dutt - Zacks Investment Research - Thu Apr 21, 9:17AM CDT
Biogen's (BIIB) first-quarter earnings were well above expectations though Tecfidera revenues declined sequentially.
BIIB: 252.54 (+1.24), EBS: 30.47 (+0.43), GILD: 86.25 (-0.30), ANIK: 52.79 (-0.51)
Global Anti-Adhesion Products Industry
PR Newswire - Mon Jun 27, 2:41PM CDT
This report analyzes the worldwide markets for Anti-Adhesion Products in US$ Thousand by the following three major Application Areas: General/Abdominal Surgery, Pelvic/Gynecological Surgery, and Other Surgical Procedures. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 21 companies including many key and niche players such as -
ANIK: 52.79 (-0.51)
Anika to Present at the Singular Research 11th Annual Spring Select Conference on June 9, 2016
BusinessWire - Thu Jun 02, 3:05PM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"
technology, today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will make a presentation at the Singular Research 11th Annual Spring Select Conference on Thursday, June 9, 2016 at 2:30 pm PT. The conference is being held at the Hilton hotel in San Francisco, CA. ANIK: 52.79 (-0.51)
Anika Announces European Commercial Launch of CINGAL for the Treatment of Pain Associated with Osteoarthritis
BusinessWire - Wed Jun 01, 8:05AM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"
technology, today announced the commercial launch of CINGAL(R), its third-generation viscosupplement, in the European Union. CINGAL, which will be initially available in Hungary, Czech Republic, Poland, Germany, and Italy, received CE Mark approval in March 2016 to treat pain associated with osteoarthritis. CINGAL will be marketed and sold in Europe by a network of experienced commercial partners under the terms of their respective commercialization agreements. ANIK: 52.79 (-0.51)
Anika Therapeutics Announces Canadian Launch of CINGAL for the Treatment of Pain Associated with Osteoarthritis of the Knee
BusinessWire - Thu May 19, 8:05AM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"
technology, today announced the commercial launch of CINGAL(R), its third-generation viscosupplement, in Canada. CINGAL received Health Canada approval in October 2015 to treat pain associated with osteoarthritis of the knee. ANIK: 52.79 (-0.51)
Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 55.01 (+0.85), OMED: 12.90 (-0.11), LGND: 126.76 (+0.90), ANIK: 52.79 (-0.51)
Alexion (ALXN) Lags Q1 Earnings & Revenues, Revises View
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:40PM CDT
Alexion (ALXN) reported earnings of 87 cents per share, below the Zacks Consensus Estimate of 91 cents.
EBS: 30.47 (+0.43), ALXN: 125.30 (+0.88), AEGR: 1.62 (-0.05), ANIK: 52.79 (-0.51)
Integra (IART) Beats on Q1 Earnings, Grows Organically
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:36PM CDT
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share (EPS) of 74 cents in the first quarter of 2016.
IART: 80.50 (-0.95), ANIP: 55.38 (-1.13), ANIK: 52.79 (-0.51), ALQA: 1.19 (unch)
GlaxoSmithKline (GSK) Q1 Earnings Lag, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:06PM CDT
Glaxo (GSK) reported first-quarter 2016 core earnings of 57 cents per American depositary share, missing the Zacks Consensus Estimate of 60 cents.
EBS: 30.47 (+0.43), GSK: 43.52 (+0.14), ANIK: 52.79 (-0.51), NVS: 82.31 (+0.18)
Baxalta (BXLT) Beats on Q1 Earnings, Set to Merge with Shire
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:41AM CDT
Baxalta's (BXLT) first-quarter 2016 earnings of 47 cents per share beat the Zacks Consensus Estimate by a penny.
BAX: 46.49 (-0.16), SHPG: 186.31 (-1.90), BXLT: 46.02 (-0.18), ANIK: 52.79 (-0.51)
Bristol-Myers (BMY) Tops Q1 Earnings, Updates 2016 View
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:27AM CDT
Bristol-Myers' (BMY) first-quarter 2016 earnings (excluding special items) of 74 cents per share easily beat the Zacks Consensus Estimate of 66 cents.
EBS: 30.47 (+0.43), PFE: 36.15 (+0.03), BMY: 75.39 (+0.11), ANIK: 52.79 (-0.51)
Celgene (CELG) Beats on Q1 Earnings, Updates '16 Outlook
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:05AM CDT
Celgene Corp. (CELG) reported first-quarter 2016 earnings of $1.18 per share (including share-based compensation expense), beating the Zacks Consensus Estimate of $1.05.
EBS: 30.47 (+0.43), AEGR: 1.62 (-0.05), ANIK: 52.79 (-0.51), CELG: 103.41 (-1.62)
Immunomedics (IMMU) Catches Eye: Stock Moves 10.8% Higher
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 7:15AM CDT
Immunomedics Inc. (IMMU) shares rose almost 11% in the last trading session.
IMMU: 2.30 (-0.18), ANIK: 52.79 (-0.51)
Downgrade Alert for Anika Therapeutics (ANIK)
Comtex SmarTrend(R) - Thu Apr 28, 3:36AM CDT
Anika Therapeutics (NASDAQ:ANIK) was downgraded from Outperform to Market Perform at Northland today. The stock closed yesterday at $44.64 on volume of 513,000 shares, above average daily volume of 148,000. There is potential upside of 14.2% for shares of Anika Therapeutics based on a current price of $44.64 and an average consensus analyst price target of $51.00. Anika Therapeutics shares have support at the 50-day moving average (MA) of $44.62 and additional support at the 200-day MA of $38.85.
ANIK: 52.79 (-0.51)
Anika beats 1Q profit forecasts
Automated Insights - Wed Apr 27, 4:05PM CDT
BEDFORD, Mass. (AP) _ Anika Therapeutics Inc. (ANIK) on Wednesday reported first-quarter earnings of $6.9 million.
ANIK: 52.79 (-0.51)
Anika Reports First Quarter 2016 Financial Results
BusinessWire - Wed Apr 27, 3:05PM CDT
--Commenced $25 million Accelerated Share Repurchase Program
ANIK: 52.79 (-0.51)
Bayer (BAYRY) Q1 Earnings Beat Estimates, Retains View
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 10:57AM CDT
Bayer (BAYRY) reported core earnings of $2.61 per share, above the Zacks Consensus Estimate of $2.48.
CYTX: 2.01 (unch), AEGR: 1.62 (-0.05), ANIK: 52.79 (-0.51)
New Strong Buy Stocks for April 27th
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:41AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
ALGN: 83.37 (+0.44), AMCX: 58.84 (-0.51), AEGR: 1.62 (-0.05), ANIK: 52.79 (-0.51), ADTN: 19.72 (+0.37)
Oncothyreon (ONTY) Catches Eye: Stock Moves 11.6% Higher
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 3:31AM CDT
Oncothyreon Inc (ONTY) shares rose almost 12% in the last trading session.
ANIK: 52.79 (-0.51), ONTY: 1.21 (+0.02)
Top 5 Stocks with Increasing Cash Flows
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 2:24PM CDT
One must look at a company's ability to produce cash - the lifeblood of business.
JBT: 63.77 (+1.14), FOR: 12.02 (-0.03), NSAT: 6.36 (-0.18), EBS: 30.47 (+0.43), ANIK: 52.79 (-0.51)
Biogen (BIIB) Tops on Q1 Earnings, Slight Revenue Miss
Arpita Dutt - Zacks Investment Research - Thu Apr 21, 9:17AM CDT
Biogen's (BIIB) first-quarter earnings were well above expectations though Tecfidera revenues declined sequentially.
BIIB: 252.54 (+1.24), EBS: 30.47 (+0.43), GILD: 86.25 (-0.30), ANIK: 52.79 (-0.51)
